Monoclonal antibody against CXCL13 to promote axonal plasticity, regeneration, and functional recovery after spinal cord injury: a translational opportunity
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110747
- Recipient
-
Imperial College Of Science, Technology And Medicine UEI T9F5NHX87N25
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $539,979
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Indianapolis, IN 46249, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $539,979 project grant to Imperial College London under the Military Medical Research and Development program. The grant will fund research from August 2021 to August 2024 to develop a monoclonal antibody targeting CXCL13 to promote axonal plasticity, regeneration, and functional recovery after spinal cord injury. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for battlefield injuries. This award will support Imperial College London's work over three years investigating a potential spinal cord injury treatment involving a monoclonal antibody that could promote nerve regeneration and improved outcomes after such injuries.
Quick answers
Who received award W81XWH2110747?
W81XWH2110747 was awarded to Imperial College Of Science, Technology And Medicine by Medical Command (Department of the Army) on August 20, 2021.
How much is award W81XWH2110747 worth?
$539,979 has been obligated on W81XWH2110747.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award